You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The company was cleared to begin a Phase I/II trial of its lead candidate, a therapeutic vaccine that can potentially treat and prevent recurrence of KRAS-mutated cancers.
The firm will begin a 100,000-patient study of its investigational liquid biopsy assay that could help bring targeted therapies into earlier lines of treatment.
In a recently published study, researchers found NTRK fusions were more common in pediatric than adult tumors and testing for them helped diagnose rare tumors.
The research may inform the use of a liquid biopsy assay for tracking SMM progression that improves on bone marrow aspirate analysis and is easier for patients to access.
The startup biotech has spent four years researching PRDM genes in various cancers and is coming out of stealth mode with a lead candidate in lung cancer.
The PARP inhibitor was found to be most cost-effective as a maintenance treatment for those with a BRCA1 mutation and who receive chemo for more than six months.
Despite promising Phase II data, ipatasertib failed to improve progression-free survival in TNBC patients with PIK3CA, AKT1, or PTEN tumor alterations.
Researchers presented updated data on the Phase III MonarchE trial at the San Antonio Breast Cancer Symposium as more patients completed the two-year treatment period.
In a retrospective analysis, ALL patients tested with NGS were less likely to achieve MRD-negative status than when tested with flow cytometry.
In the study, more than 80 percent of multiple myeloma patients with BRAF V600E mutations saw their tumor shrink after receiving Braftovi and Mektovi.